Merck ’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer
Dateline City:
KENILWORTH, N.J. First Presentation of Data from Phase 3 KEYNOTE-045 Study Presented at the Society for Immunotherapy of Cancer ’s (SITC) 31 st Annual MeetingKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced results from the pivotal KEYNOTE-045 study investigating
the use of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1
therapy, in patients with advanced bladder (urothelial) cancer
previously treated with platinum-containing chemotherapy. As previously
announced, KEYTRUDA was superior to investigator-choice chemotherapy for
the primary endpoint of overall survival (OS) in this phase 3 study, and
was stopped early.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Immunotherapy | Merck | Study